Holen Sie sich die Stockscreener-App
0.9501
0.77%
-0.0074
Handel nachbörslich:
.95
-0.000100
-0.01%
Schlusskurs vom Vortag:
$0.9575
Offen:
$0.95
24-Stunden-Volumen:
1.69M
Relative Volume:
0.48
Marktkapitalisierung:
$273.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-2.5678
EPS:
-0.37
Netto-Cashflow:
$-72.53M
1W Leistung:
-1.37%
1M Leistung:
-5.93%
6M Leistung:
-28.56%
1J Leistung:
+146.78%
1-Tages-Spanne:
$0.93
$0.96
1-Wochen-Bereich:
$0.9032
$1.02
52-Wochen-Spanne:
$0.351
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Vanguard Group Inc's Strategic Acquisition of Shares in Ocugen I - GuruFocus.com
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase - MSN
Ocugen (OCGN) Set to Announce Earnings on Friday - MarketBeat
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163% - Yahoo Finance
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - Ocugen
Ocugen Clinical Showcase Highlighting Progress in Retinal - GlobeNewswire
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy - MSN
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
HC Wainwright Reiterates Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - Ocugen
Ocugen advances to phase 2 in Stargardt disease trial - Investing.com
Data and Safety Monitoring Board Approves Initiation of - GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at - GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - StockTitan
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc - Yahoo Finance
Ocugen Inc. stock outperforms market despite losses on the day - MarketWatch
Maxim Group sees Ocugen shares as a buy, cites financial position - Investing.com
Ocugen (NASDAQ:OCGN) Receives New Coverage from Analysts at Maxim Group - MarketBeat
Ocugen Advances Promising Pipeline Amid Financial Restraints - Nasdaq
Ocugen’s CEO to Present at 2024 Maxim Healthcare Virtual Summit - MSN
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit - Ocugen
Ocugen says FDA has removed clinical hold on eye drug OCU200 - MSN
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial - Ocugen
FDA lifts hold on Ocugen's DME drug trial - Investing.com
Ocugen Says FDA Lifts Clinical Hold on Diabetic Macular Edema Drug - MarketWatch
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for - The Bakersfield Californian
Ocugen, Inc. Announces Removal of Clinical Hold on - GlobeNewswire
Ocugen, Inc. to Feature at Chardan’s Genetic Medicines Conference - MSN
WashU COVID-19 nasal vaccine technology licensed to Ocugen - WashU Medicine
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cheese Block (BGU25) Quote - The Globe and Mail
Ocugen, Inc. Set to Present at 2024 Cell & Gene Meeting on the Mesa - MSN
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - Ocugen
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Profund Advisors LLC Invests $227,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MSN
Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares - openPR
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):